Q1 2025 Guardant Health Inc Earnings Call Transcript
Key Points
- Guardant Health Inc (GH) reported a strong start to the year with Q1 revenue growing 21% year-over-year to $203 million.
- The company achieved positive gross margins for both Reveal and Shield in Q1 2025, driven by significant cost reductions.
- Guardant360 ASP improved to the range of $3,000 to $3,100, supported by better Medicare Advantage and commercial reimbursement.
- The company announced a strategic collaboration with Pfizer, enhancing its long-term partnership and expanding its biopharma business.
- Shield received ADLT status, increasing the Medicare price from $920 to $1,495, which is expected to accelerate commercial infrastructure buildout.
- Despite the positive results, Guardant Health Inc (GH) continues to report an adjusted EBITDA loss, with a $58.5 million loss for Q1 2025.
- Free cash flow burn increased to $67 million in Q1 2025, compared to $37 million in the prior year period, due to timing of bonus payouts.
- The company faces challenges in scaling its Shield business, with a significant portion of its cash burn related to screening efforts.
- There is uncertainty regarding the timing of guideline inclusion for Shield, which could impact commercial adoption and volume growth.
- The company is still in the early stages of deploying its sales force for Shield, with full productivity expected to take 12 to 18 months.
Hello, everybody, and welcome to the Guardant Health Q1 2025 earnings call. My name is Elliot, and I'll be your coordinator today. (Operator Instructions) I would now like to hand over to Zarak Khurshid, Vice President of Investor Relations. Please go ahead.
Thank you. Earlier today, Guardant Health released financial results for the quarter ended March 31, 2025. Joining me today from Guardant are Helmy Eltoukhy, Co-CEO; AmirAli Talasaz, Co-CEO; and Mike Bell, Chief Financial Officer. Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated.
This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specified items. Additional information regarding material risks and uncertainties as well as the non-GAAP
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
